MediciNova, Inc.
Fiscal Year Ending December 2026 Q2 Interim Financial Results Report [U.S. GAAP] (Consolidated)
The consolidated results for the second quarter of the fiscal year ending December 2026 show continued losses. Revenue is 645,423 thousand USD (interim), operating loss is △5,376,995 thousand USD, net loss attributable to parent company shareholders for the interim is △4,900,397 thousand USD. The full-year guidance for the fiscal year ending December 2026 has not been disclosed at this time. Yorkville SEPA and Lucid sale agreements are retained; cash is 25.4 million USD, working capital is 23.0 million USD. Key financials include current assets about 25.9 million USD, shareholders’ equity about 37.3 million USD.
Key Figures
- Revenue: 645,423
- Interim net loss: △4,900,397
- Cash and cash equivalents: 25,415,921
AI要約
Summary of Results
This earnings report discloses the interim period results under U.S. GAAP: revenue of 645,423 thousand USD, operating loss of △5,376,995 thousand USD, and interim net loss of △4,900,397 thousand USD. No full-year guidance has been published at this time. Cash and cash equivalents amount to 25,415,921 thousand USD, and shareholders’ equity stands at 37,270,602 thousand USD. Financing arrangements via Yorkville SEPA provide up to 30.0 million USD, and a stock sale agreement via Lucid remains up to 50.0 million USD.
Capital Policy and Financing Trends
During the interim period, the Company retains the right to periodically dispose of shares via Yorkville. Structuring fees and commitment fees payable to Yorkville have been paid. The stock sale agreement via Lucid has not been executed at this time. Attention to cash generation stability is required, and working capital is expected to be secured through November 2027, though this does not guarantee full funding of all programs.
Medicinova, Inc.
Company overview · Stock price · Financial data · All IR
